THE ROLE OF CYTOKINE GENES POLYMORPHISM IN HEPATITIS C VIRUS INFECTION

Cover Page


Cite item

Full Text

Abstract

Abstract. The outcome of hepatitis C virus (HCV) infection depends on the immune response caused by the host genetic factors. Cytokines are key mediators of inflammation and development of specific immunity, which is responsible for the elimination of HCV. It has been found that the polymorphisms in several cytokine genes play role in human susceptibility to HCV infection, determine its differences in response to HCV and treatment-induced HCV clearance. This review summarizes the results of studies on the single-nucleotide polymorphisms of cytokine genes that complete our knowledge of the pathogenesis of HCV infection.

About the authors

N. A. Arsentieva

ФБУН НИИ эпидемиологии и микробиологии имени Пастера, Санкт-Петербург

Author for correspondence.
Email: arsentieva_n.a@bk.ru

научный сотрудник лаборатории молекулярной иммунологии и сероэпидемиологии

197101, Санкт-Петербург, ул. Мира, 14

Россия

A. V. Semenov

ФБУН НИИ эпидемиологии и микробиологии имени Пастера, Санкт-Петербург

Email: arsentieva_n.a@bk.ru
Россия

Areg A. Totolian

ФБУН НИИ эпидемиологии и микробиологии имени Пастера, Санкт-Петербург

Email: arsentieva_n.a@bk.ru
Россия

References

  1. Генетический паспорт — основа индивидуальной и предиктивной медицины / Под ред. В.С. Баранова. — СПб.: ООО «Издательство Н-Л». — 2009. — 528 с.
  2. Жданов К.В., Гусев Д.А., Сысоев К.А., Якубовская Л.А., Шахманов Д.М., Тотолян А.А. Изучение экспрессии хемокинов и их рецепторов в крови и ткани печени при хронической HCV-инфекции // Клин. перспективы гастроэнтерол., гепатол. — 2007. — № 6. — С. 3–10.
  3. Жданов К.В., Гусев Д.А., Чирский В.С., Сысоев К.А., Якубовская Л.А., Шахманов Д.М., Тотолян А.А. Экспрессия хемокинов и их рецепторов в крови и ткани печени при хроническом гепатите С // Медицинская иммунология. — 2007. — № 4. — С. 379–388.
  4. Наследникова И.О., Рязанцева Н.В., Белобородова Е.В. Иммунорегуляторные цитокины и хронизация вирусного гепатита С: клинико-иммунологические параллели // Клин. медицина. — 2005. — № 9. — С. 40–44.
  5. Никитин В.Ю., Сухина И.А., Иванов А.М., Арсентьева Н.А., Ширина И.В. Активационные маркеры Т-лимфоцитов у больных хроническим гепатитом С // Росс. аллергол. журн. — 2010. — № 5. — С. 208–209.
  6. Новицкий В.В., Бычков В.А., Семенова Н.А., Рязанцева Н.В., Клепцова Л.А., Якушина В.Д. Ассоциация полиморфизмов генов системы интерферона 0AS-1, OAS-3, PKR и хронического вирусного гепатита С // Медицинская иммунология. — 2011. — № 1. — С. 93–100.
  7. Ярилин А.А. Иммунология. — М.: ГЭОТАР-Медиа, 2010. — 749 с.
  8. Afzal M.S., Tahir S., Salman A., Baig T.A., Shafi T., Zaidi N.U., Qadri I. Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan // J. Infect. Dev. Ctries. — 2011. — Vol. 5, N 6. — P. 473–479.
  9. Ahmad A., Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis // J. Leukoc. Biol. — 2004. — Vol. 76, N 4. — P. 743–759.
  10. Alter H.J. Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome // Semin. Liver Dis. — 2000. — Vol. 20, N 1. — P. 17–35.
  11. Bertoletti A., Maini M.K. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? // Curr. Opin. Immunol. — 2000. — Vol. 12. — P. 403–408.
  12. Bream J.H., Carrington M., O'Toole S., Dean M., Gerrard B., Shin H.D. Polymorphisms of the human IFNG gene noncoding regions // Immunogenetics. — 2000. — Vol. 51. — P. 50–58.
  13. Butera D., Marukian S., Iwamaye A.E., Hembrador E., Chambers T.J., Di Bisceglie A.M., Charles E.D., Talal A.H., Jacobson I.M., Rice C.M., Dustin L.B. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C // Blood. — 2005. — Vol. 106. — P. 1175–1182.
  14. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa // Hepatology. — 1996. — Vol. 24. — P. 6–9.
  15. Casrouge A., Decalf J., Ahloulay M., Lababidi C., Mansour H., Vallet-Pichard A., Mallet V., Mottez E., Mapes J., Fontanet A., Po S., Albert M.L. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV // J. Clin. Invest. — 2011. — Vol. 121, N 1. — P. 308–317.
  16. Dahari H., Guedj J., Perelson A.S., Layden T.J. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL-28B // Curr. Hepat. Rep. — 2011. — Vol. 10, N 3. — P. 214–227.
  17. Dai J., Megjugorac N.J., Gallagher G.E., Yu R.Y., Gallagher G. IFNlambda1 (IL-29) inhibits GATA3 epression and suppresses Th2 responses in human naive and memory T cells // Blood. — 2009. — Vol. 113. — P. 5829–5838.
  18. Dev A.T., McCaw R., Sundararajan V., Bowden S., Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome // Hepatology. — 2002. — Vol. 36. — P. 1259–1265.
  19. Dogra G., Chakravarti A., Kar P., Chawla Y.K. Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response // Hum. Immunol. — 2011. — Vol. 72, N 10. — P. 935–939.
  20. Gao Q.J., Liu D.W., Zhang S.Y., Jia M., Wang L.M., Wu L.H., Wang S.Y., Tong L.X. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection // World J. Gastroenterol. — 2009. — Vol. 15, N 44. — P. 5610–5619.
  21. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchi son J.G., Goldstein D.B. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearan ce // Nature. — 2009. — Vol. 461. — P. 399–401.
  22. Hall M.A., McGlinn E., Coakley G., Fisher S.A., Boki K., Middleton D., Kaklamani E., Moutsopoulos H., Loughran T.P. Jr, Ollier W.E., Panayi G.S., Lanchbury J.S. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease // Genes Immun. — 2000. — Vol. 1. — P. 219–224.
  23. Helbig K.J., George J., Beard M.R. A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro // J. Clin. Virol. — 2005. — Vol. 32. — P. 137–143.
  24. Hellier S., Frodsham A.J., Hennig B.J., Klenerman P., Knapp S., Ramaley P., Satsangi J., Wright M., Zhang L., Thomas H.C., Thursz M., Hill A.V. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection // Hepatology. — 2003. — Vol. 38. — P. 1468–1476.
  25. Honda M., Sakai A., Yamashita T., Nakamoto Y., Mizukoshi E. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C // Gastroenterology. — 2010. — Vol. 139. — P. 499–509.
  26. Hoofnagle H.J., Wahed A.S., Brown R.S., Howell C.D., Belle S.H. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection // J. Inf. Dis. — 2009. — Vol. 199. — P. 1112–1120.
  27. Houldsworth A., Metzner M., Rossol S., Shaw S., Kaminski E., Demaine A.G. Polymorphisms in the IL-12B gene and outcome of HCV infection // J. Interferon Cytokine Res. — 2005. — Vol. 25. — P. 271–276.
  28. Huang Y., Yang H., Borg B.B., Su X., Rhodes S.L., Yang K., Tong X., Tang G., Howell C.D., Rosen H.R., Thio C.L., Thomas D.L., Alter H.J., Sapp R.K., Liang T.J. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection // Proc. Natl. Acad. Sci. USA. — 2007. — Vol. 104. — P. 985–990.
  29. Ishida C., Ikebuchi Y., Okamoto K., Murawaki Y. Functional gene polymorphisms of interleukin-10 are associated with liver disease progression in Japanese patients with hepatitis C virus infection // Intern. Med. — 2011. — Vol. 50, N 7. — P. 659–666.
  30. Jordan W.J., Eskdale J., Srinivas, S., Pekarek V., Kelner D., Rodia M., Gallagher G. Human interferon lambda-1 (IFNlambda1/IL-29) modulates the Th1/Th2 response // Genes Immun. — 2007. — Vol. 8. — P. 254 –261.
  31. Kelly C., Klenerman P., Barnes E. Interferon lambdas: the next cytokine storm // Gut. — 2011. — Vol. 60. — P. 1284 –1293.
  32. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., Cheng J., Goedert J.J., Vlahov D., Hilgartner M., Cox S., Little A.M., Alexander G.J., Cramp M.E., O’Brien S.J., Rosenberg W.M., Thomas D.L., Carrington M. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection // Science. — 2004. — Vol. 305. — P. 872–874.
  33. Marcello T., Grakoui A., Barba-Spaeth G. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics // Gastroenterology. — 2006. — Vol. 131. — P. 1887–1898.
  34. Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., Hallahan C.W., Selig S.M., Schwartz D., Sullivan J., Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors // Proc. Natl. Acad. Sci. USA. — 2000. — Vol. 97. — P. 2709–2714.
  35. Mosbruger T.L., Duggal P., Goedert J.J., Kirk G.D., Hoots W.K., Tobler L.H., Busch M., Peters M.G., Rosen H.R., Thomas D.L., Thio C.L. Large-Scale candidate gene analysis of spontaneous hepatitis C virus clearance // J. Infect. Dis. — 2010. — Vol. 201, N 9. — P. 1371–1380.
  36. Mueller T., Mas-Marques A., Sarrazin C., Wiese M., Halangk J., Witt H., Ahlenstiel G., Spengler U., Goebel U., Wiedenmann B., Schreier E., Berg T. Influence of interleukin 12B (IL-12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection // J. Hepatol. — 2004. — Vol. 41. — P. 652–658.
  37. Oleksyk T.K., Thio C.L., Truelove A.L., Goedert J.J., Donfield S.M., Kirk G.D., Thomas D.L., O’Brien S.J., Smith M.W. Single nucleotide polymorphisms and haplotypes in the IL-10 region associated with HCV clearance // Genes Immun. — 2005. — Vol. 6. — P. 347–357.
  38. Pagliaccetti N.E., Eduardo R., Kleinstein S.H., Mu X.J., Bandi P., Robek M.D. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication // J. Biol. Chem. — 2008. — Vol. 283. — P. 30079–30089.
  39. Pekarek V., Srinivas S., Eskdale J., Gallagher G. Interferon lambda-1 (IFNlambda1/IL-29) induces ELR(–) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFNgamma-independent manner // Genes Immun. — 2007. — Vol. 8. — P. 177–180.
  40. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J. Genetic variation in IL-28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study // Gastroenterology. — 2010. — Vol. 138, N 4. — P. 1338–1345.
  41. Seegers D., Zwiers A., Strober W., Pena A.S., Bouma G. A TaqI polymorphism in the 3’UTR of the IL-12 p40 gene correlates with increased IL-12 secretion // Genes Immun. — 2002. — Vol. 3. — P. 419–423.
  42. Shackel N.A., McCaughan G.W. Intrahepatic interferon-stimulated gene responses: can they predict treatment responses in chronic hepatitis C infection? // Hepatology. — 2007. — Vol. 46. — P. 1326–1328.
  43. Sheppard P., Kindsvogel W., Xu W. IL-28, IL-29 and their class II cytokine receptor IL-28R // Nat. Immunol. — 2003. — Vol. 4. — P. 63–68.
  44. Srinivas S., Dai J., Eskdale J., Gallagher G.E., Megjugorac N.J., Gallagher G. Interferonlambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro // Immunology. — 2008. — Vol. 125. — P. 492–502.
  45. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Müller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL-28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy // Nat. Genet. — 2009. — Vol. 41. — P. 1100–1104.
  46. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C // Nat. Genet. — 2009. — Vol. 41. — P. 1105–1109.
  47. Taniguchi T., Ogasawara K., Takaoka A. IRF family of transcription factors as regulators of host defense // Annu. Rev. Immunol. — 2001. — Vol. 19. — P. 623– 655.
  48. Thio C.L. Host genetic factors and antiviral immune responses to hepatitis C virus // Clin. Liver Dis. — 2008. — Vol. 12. — P. 713–725.
  49. Thio C.L., Goedert J.J., Mosbruger T.l., Vlahov D., Strathdee S.A., O’Brien S.J., Astemborski J., Thomas D.L. An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection // Genes Immun. — 2004. — Vol. 5. — P. 294–300.
  50. Thio C.L., Thomas D.L., Goedert J.J., Vlahov D., Nelson K.E., Hilgartner M.W., O’Brien S.J., Karacki P., Marti D., Astemborski J., Carrington M. Racial differences in HLA class II associations with hepatitis C virus outcomes // J. Infect. Dis. — 2001. — Vol. 184. — P. 16 –21.
  51. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O’Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus // Nature. — 2009. — Vol. 461. — P. 798–801.
  52. Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., Nolt K., Nelson K.E., Strathdee S.A., Johnson L., Laeyendecker O., Boitnott J., Wilson L.E., Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environ mental factors // JAMA. — 2000. — Vol. 284, N 4. — P. 450–456.
  53. Tsunemi Y., Saeki H., Nakamura K., Sekiya T., Hirai K., Fujita H., Asano N., Kishimoto M., Tanida Y., Kakinuma T., Mitsui H., Tada Y., Wakugawa M., Torii H., Komine M., Asahina A., Tamaki K. Interleukin-12 p40 gene (IL-12B) 3’-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris // J. Dermatol. Sci. — 2002. — Vol. 30. — P. 161–166.
  54. Viral hepatitis selected issues of pathogenesis аnd diagnostics / Ed. by Mukomolov S.L. — Intechweb.org., 2011. — 152 p.
  55. Wald O., Pappo O., Ari Z.B., Azzaria E., Wiess I.D., Gafnovitch I., Wald H., Spengler U., Galun E., Peled A. The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection // Eur. J. Immunogenet. — 2004. — Vol. 31, N 6. — P. 249–252.
  56. Woitas R.P., Ahlenstiel G., Iwan A., Rockstroh K., Brackmann H.H., Kupfer B., Matz B., Offergeld R., Sauerbruch T., Spengler U. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C // Gastroenterology. — 2002. — Vol. 122. — P. 1721–1728.
  57. Yee L.J. Host genetic determinants in hepatitis C virus infection // Genes Immun. — 2004. — Vol. 5. — P. 237–245.
  58. Yin L.M., Zhu W.F., Wei L., Xu X.Y., Sun D.G., Wang Y.B. Association of interleukin-12 p40 gene 3’-untranslated region polymorphism and outcome of HCV infection // World J. Gastroenterol. — 2004. — Vol. 10. — P. 2330–2333.
  59. .95Zeremski M., Markatou M., Brown Q.B., Dorante G., Cunningham-Rundles S., Talal A.H. Interferon gammainducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients // J. Acquir. Immune. Defic. Syndr. — 2007. — Vol. 45. — P. 262–268.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Arsentieva N.A., Semenov A.V., Totolian A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies